We describe an 1251-based RIA for cotinine, the major metabollte of nicotine. The slope of the dose-response curve was quite shallow (6-8% change in binding per doubling dose), resulting in between-assay CVs of 15 to 20%. This effect occurred because the radioligand formed by linking a cotinine derivative to tyramine manifested greater affinity for the anti-cotinine antibodies than did cotinine itself. We absorbed the serum with a derivative of nicotine coupled to the carrier protein via a chemical bridge similar to that used to form the cotinine/carrier protein immunogen. An AlA in which we used such absorbed serum showed a significantly increased slope of the dose-response curve (11-13% change in binding per doubling dose), and between-assay CVS were only 6 to 8%. We suggest that this improvement results because absorption removes anti-bridge antibodies directed against the chemical bond common to the cotinine/carrierprotein immunogen and to the cotinine/tyramine radioligand.
the blood, urine, and saliva of individuals who smoke or chew tobacco or who inhale tobacco smoke produced by others. As an objective indicator of nicotine intake or confirmation of nonsmoker status, cotinine offers several advantages over other biochemical measures: it is a specific indicator of nicotine intake, its concentrations are not influenced by confounding factors such as diet or environment, its average biological half-life in blood is 19 h, and its concentration within a given individual varies by only 15 to 20% over the course of a day (1). Cotimne assay is thus a superior objective measure of exposure to nicotine (2) (3) (4) (5) (6) (7) (8) (9) .
We describe here a radioimmunoassay for cotinine, based on the method of Langone and Van Vunakis (10), for use in (e.g.) the study of smoking-associated health risks during pregnancy. Those authors described use of both tritium and I tracers. Preparation of the tritium label requires catalytic exchange labeling of (-)nicotine, enzymic oxidation of (-)mcotine to (-)cotinine by using rabbit liver extract, and liquid-chromatographic purification of the final product. Because of the expense and inconvenience of this approach, we elected to use the 1251 tracer. However, the slope of the dose-response curve was quite shallow, resulting in relatively high imprecision.
Both a shallow dose-response curve and loss of sensitivity have been described for other assays involving 1251-labeled haptens (11). These phenomena are related to the fact that the chemical bridge linking the hapten to the carrier protein to form the immunogen is identical to that which links the hapten to an iodinatable derivative. The radioligand reacts with the anti-bridge antibodies elicited by the immunogen, thereby manifesting greater affinity for the antiserum than does the hapten itself. iodinatable derivative and the hapten, link the iodinatable derivative to a different position on the hapten, or screen antisera to find one that yields acceptable performance (11). Our alternative approach was to alter the reactivity of the antiserum itself we remove the anti-bridge antibodies by absorbing the hapten (cotinine) antiserum with a conjugate formed between a compound structurally related to the hapten (nicotine) and a carrier protein linked to the hapten via a similar chemical bond. Here, we report the improved assay resulting from use of the absorbed antiserum. Cotinine standards were prepared by adding cotimne funiarate to pooled human serum obtained from nonsmokers whose exposure to smokers was neglible. Blood was sampled monthly, starting one week after the second booster. Anti-cotinine titers were evaluated by determining what dilution of 0.1 mL of immune rabbit serum bound 50% of the input tracer under standard assay conditions. lodinating the radioligand:
Materials and Methods

Reagents and Standards
To 2.0 g of the tyramine derivative of NCC, dissolved in 100 pL of sodium phosphate buffer (0.5 mollL, pH 7.5), add 1.5 mCi of Na1251. Vortexmix, add 10 L of an 8 g/L Chloramine T solution in potassium phosphate buffer (0.1 molJL, pH 7.5), and again mix. After 30 s, add 20 L of an 8 g/L solution of sodium metabisulfate in the potassium phosphate buffer. Apply the iodination mixture to a 5.0-mL column of DE-52 equilibrated with another potassium phosphate buffer (10 mmol/L, pH 8.0). Elute with that same buffer and collect 1.0-mL fractions into 0.5 mL portions of the pH 7.5 potassium phosphate buffer. Monitor the radioactivity and pool those fractions having peak activity. This radioligand can be stored at 4#{176}C in the pH 7.5 phosphate buffer for as long as two months. The estimated specific activity is 500 CiIg.
Preparation of KLH/succinylated trans-3' -hydroxymethylnicotine (nicotine/KLH):
Dissolve 500 mg of succinylated trans-3'-hydroxymethylnicotine in 10 mL of the pH 8.0 potassium phosphate buffer, then add 500 mg KLH dissolved in same buffer. Add 500 mg of 1-ethyl-3-(3-dimethylamino)propylcarbodiimide hydrochloride, and stir at room temperature for 3 h. Let stand at 4#{176}C overnight, then dialyze against isotonic saline as described above for the preparation of immunogen. Store at 4#{176}C, at a concentration of 10 g/L.
Absorption of rabbit anti-cotinine serum with nicotine/ KLH immunoabsorbent:
To 10 mL of rabbit anti-cotinine antiserum add 10 mg of KLH, stirring to dissolve. Incubate at 37#{176}C for 1 h, then centrifuge at 2000 x g for 15 mm. Decant the supernatant fluid and discard the pellet. Add 5 mg of KLH and stir to dissolve. After incubating this mixture at 4 #{176}C overnight, add to it an equal volume (12 mL) of 80 g/L polyethylene glycol, mix well, and centrifuge at 3000 x g for 30 mm. Remove the supernate and add to it 2 mL of the 10 g/L nicotine/KLH conjugate. Stir at room temperature for 5 h, then let stand at 4#{176}C overnight. Centrifuge (13 000 x g, 1 h, 4#{176}C) and store aliquots of the supernate at -20 #{176}C until needed. Express all radioactivity (counts/mn) as a percentage of the radioactivity of the zero cotinine standard (B/B0).
Improved separation procedure.
When we carried out the studies reported here, we separated bound and free radioactivity by adding 1.0 mL of 3.8 mol/L ammonium sulfate to each reaction tube, vortex-mixing, and letting the mixture stand at room temperature for 15 mm, then placing the reaction tubes in a water bath at 4-8 #{176}C for an additional 15 mm before centrifugation. After these studies were completed, we developed a separation system involving polyethylene glycol 8000, which is independent of time and temperature and shows lower nonspecific binding. This separation method, which we recommend for all clinical studies in place of the ammonium sulfate procedure just described, is as follows: add 1.0 mL of 300 g/L polyethylene glycol in isotonic saline to the reaction mixture, vortex-mix vigorously, and centrifuge without delay.
Comparison assay: Using our '251-based cotinine assay, we determined cotinine in 47 smokers' urines collected as part of a previous study (12) 
Results
Selection of Cotinine Antiserum
All of five immunized rabbits produced anti-cotinine antibody at titers of at least 1:20 six months after the immunization schedule was begun. One responded significantly more strongly than the others, achieving a titer of greater than 1:200. After absorption of immune serum from this rabbit with nicotine/KL}{ conjugate, the residual titer exceeded 1:150; in all others, it declined to below 1:20. We pooled and absorbed the antisera from four bleedings from the hightiterrabbit and used the resulting antiserum for the studies described. Cotinine antiserum sufficient for 300 000 assays was obtained from this pool.
Antiserum Characteristics before and after Absorption
We evaluated the performance of the assay for cotinine by using unabsorbed antiserum and antiserum absorbed with nicotinefKLH at the same dilution (1:210) (Figure 2 ). Unabsorbed antiserum produced a shallow dose-response curve, and 52% of the label was still bound in the presence of a great excess of cold cotinine (400 000 pg/L). Use of the absorbed antiserum significantly increased the slope of the standard curve and shifted it to the left. The slope of the standard curve for the absorbed antibody in the range of cotinine concentrations found in most smokers (100-500 igiL) is 11.5% per doubling dose, as compared with 8.0% for the unabsorbed antibody. Furthermore, only 11.0% of the input count was now bound in the presence of excess nonradioactive cotinine. The extent of the assay curve shift after absorption can be approximated by comparing the cotiine concentrations at the mid-point of the dose-response curves, i.e., assigning a binding of 100% to the count for the zero cotinine standard and 0% to the count for the 400 000 p.g/L standard. The midpoint cotinine value is 340 g/L for the unabsorbed antibody and 110 ig/L for the absorbed antibody, a more than threefold displacement.
Cross Reactivity of Tyramine Derivative (NCC) and Cotinine
To discover whether the steeper slope of the standard curve after absorption resulted from decreased affinity of the tracer for the antiserum, we determined inhibition of binding, using known concentrations of cotinine and of unlabeled tracer (NCC). For both absorbed and unabsorbed antibody, NCC is a more effective competitor of iodinated NCC than is cotinine itself, although the dose-response curves are nonparallel (Figure 3, a and b) . However, if the relative concentrations of NCC and cotinine required to yield a given percentage of inhibition are compared, cotinine competes with tracer more effectively when absorbed rather than unabsorbed antiserum is used. This is shown in Figure  4 , where the ratio of cotinine to NCC resulting in equal inhibition of tracer binding is plotted vs cotinine concentration. At concentrations exceeding 125 g/L, cotinine competed more effectively with the tracer with use of absorbed antibody.
Precision
Within-assay.
The within-assay CV when absorbed antibody was used was found by comparing means of replicates from four separate assays. Within-assay CVs covering the range of cotinine values found in smokers' sera were 4.6-6.2% (Table 1) .
Between-assay
precision and analytical recovery. Cotinine was added to serum from non-smoking individuals to give pools corresponding to low, medium, and high values. We ran these in 19 separate assays, using absorbed antibody, and calculated recoveries and CVs. Results were close to that expected ( Table 2) .
Cross Reactivity with Nicotine
Because nicotine is present in significant amounts in smokers' serum, we determined the cross reactivity of absorbed antiserum with this closely related substance. At 50% inhibition on the dose-response curve it is necessary to COTININE 4tg/L) add 221 nmol of nicotine to obtain the same inhibition as 0.8 nmol of cotiine, yielding a cross reactivity of 1/276. Cross reactivity in the assay when unabsorbed antiserum is used was 1/249. 
Discussion
Our initial RIA for cotinine performed satisfactorily (9), but was relatively imprecise because of a shallow doseresponse curve. We speculated that this was because the 125j tracer was more reactive with anti-cotinine serum than was cotinine itself because of the presence of antibodies directed against the chemical bridge common to both the cotininel KLH immunogen and the tracer.
Our approach to improving the cotinine assay was to remove anti-bridge antibodies by absorbing the antiserum with a closely related compound coupled to the carrier protein KLH via a similar or identical chemical bridge.
Nicotine was an obvious choice for making the absorbing conjugate because (a) it is structurally similar to cotinine, differing only by a ketone group on the pyrollidine ring; (b) it exhibits minimal cross reactivity with cotinine, precluding removal of hapten antibodies during absorption; and (c) it can be derivatized with a carboxyl group at the same ring position as cotinine (10). That this strategy was reasonable is evidenced by the steeper slope and greater sensitivity of the assay with use of absorbed antisera.
To ascertain whether or not this improvement resulted from a decreased affinity of the tracer for the cotinine antiserum, we determined the relative reactivity of unlabeled NCC and cotinine, using absorbed and unabsorbed antiserum. NCC was a better competitor of the tracer than cotinine at all points on the dose-response curve for both sera. However, for cotinine concentrations exceeding 125 g/L, the amount of cotinine required to give a binding inhibition equal to that of NCC was considerably lower for an assay involving absorbed antiserum-and this effect was antiserum is used. However, the effect is less pronounced than that above 125 g/L, and the net result is a considerably improved assay.
A solid-phase immunoabsorbant made by coupling a succmnylated nicotine derivative to an amino terminal agarose gel with a hydrophilic arm was totally ineffective as an absorbent. It appears that bridge antibodies are only removed when the nicotine derivative is recognized in the context of the carrier protein KLH, perhaps because of steric factors.
The cross reactivity of nicotine and cotinine decreased by only 10% after absorption (1/294 vs 1/276), We had anticipated that absorption might remove most of the antibodies common to nicotine and cotinine. That this did not occur suggests that cotimne elicits an antibody response directed primarily at the ketone group of the 2-pyrrolidone ring of the cotinine molecule.
Cotinine assay in body fluids are of increasing importance in assessing both active and passive intake of nicotine for studies of effects of tobacco consumption on health. 125J based RIA is a convenient method for measuring cotinine when large numbers of clinical samples are to be assayed, offering lower cost, simplified handling, and more rapid throughput (with multi-head counters) as compared with tritium-based assays. The methodology described herein will allow those investigators desiring an '251-based cotinine assay to achieve precision comparable to that obtained with tritium-based assays.
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